Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

After reanalyzing data from 500,000 people in Israel who received the Pfizer vaccine, researchers suggest a single dose provides sufficient immunity after about 21 days, thus providing support for the UK’s decision to delay the second dose to 12 weeks.

4 Feb 2021

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

A new study reports the underlying basis of increased transmissibility in the N501Y UK variant and provides reassuring data on the efficacy of the Pfizer vaccine and Eli Lilly monoclonal antibodies in neutralizing it.

4 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

Study shows how SARS-CoV-2 evades immune responses

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the University of Pittsburgh School of Medicine.

4 Feb 2021

SARS-CoV-2 has developed worrying new mutation in UK

Over the past few months, surging cases have been reported due to new fast-spreading variants. Now, Public Health England (PHE) investigates cases of COVID-19 with worrying new genetic changes. The E484K mutation, which could allow SARS-CoV-2 escape antibody protection, was seen in a small group of cases in some regions of the country.

4 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today.

3 Feb 2021

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Researchers in the UK, South Africa and Brazil have reported the latest efficacy results from phase III trials of the Oxford–AstraZeneca vaccine currently being rolled out in the UK to protect against coronavirus disease 2019 (COVID-19).

3 Feb 2021

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Moffitt researchers reveal why some ovarian cancer patients evolve better than others

The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

A new study describes the antiviral activity of oxysterols, or oxidized cholesterol derivatives, against SARS-CoV-2. These occur in nature, and are not only involved in lipid signaling pathways that modulate a host of processes within the body, including the immune response and lipid homeostasis.

3 Feb 2021

Study finds higher pediatric SARS-CoV-2 burden than previously reported in the U.S.

In a new study, published on the pre-print server medRxiv*, researchers at Inova Children's Hospital and the George Mason University revealed that a much higher burden of SARS-CoV-2 infection was found in children than previously reported. This comes after the researchers assessed seropositivity among 1,038 children and adolescents.

3 Feb 2021

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

The SARS-CoV-2, the new coronavirus behind the current pandemic, infects humans by binding its surface-exposed spike proteins to ACE2 receptors exposed on the cell membranes.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19.

2 Feb 2021

Antibody News and Research

Further Reading

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Study shows how SARS-CoV-2 evades immune responses

SARS-CoV-2 has developed worrying new mutation in UK

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

Insight into role of aging in response to SARS-CoV-2 infection

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Experimental intranasal influenza vaccine produces durable immune response

Moffitt researchers reveal why some ovarian cancer patients evolve better than others

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

Study finds higher pediatric SARS-CoV-2 burden than previously reported in the U.S.

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo